Advanz Zeroes In On Innovative Assets And M&A
Business Has Increased In Value To Around €670m
Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.
You may also be interested in...
As Advanz completes its deal to acquire Intercept’s ex-US business, the company has confirmed a management change that has seen chief commercial officer Paul Burden leave the company, with the appointment of two new regional CCOs.
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.
In 2024, Viatris will initiate the second phase of its long-term business plan, which will see it step away from the perceived volatility of the generics space and begin to move toward innovative and high-growth products. The past year has seen it lay the groundwork for this pivot, shedding surplus business units and making significant hires from the branded space.